Page last updated: 2024-12-08

cerivastatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446156
CHEMBL ID1477
CHEBI ID3558
CHEBI ID94755
SCHEMBL ID16346
SCHEMBL ID16347
MeSH IDM0228730

Synonyms (51)

Synonym
chebi:3558 ,
cerivastatin acid
BIDD:GT0367
(3r,5s,6e)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
(3r,5s,e)-7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoic acid
AB01275453-01
gtpl2950
(3r,5s,6e)-7-{4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(methyloxy)methyl]pyridin-3-yl}-3,5-dihydroxyhept-6-enoic acid
D07661
cerivastatin (inn)
[s-[r*,s*-(e)]]-7-[4-(4-fluorophenyl)-5-methoxymethyl)-2,6bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoate
cerivastatin
C07966
DB00439
cerivastatin [inn:ban]
6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3r,5s,6e)-
(3r,5s,6e)-7-(4-(p-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid
hsdb 7357
6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))-
(3r,5s,6e)-7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid
cervastatin
(3r,5s,6e)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
bdbm18376
HMS2089B11
CHEMBL1477
(e,3r,5s)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
am91h2ks67 ,
unii-am91h2ks67
159813-78-2
cerivastatin sodium salt hydrate
cerivastatin [vandf]
cerivastatin [inn]
cerivastatin [mi]
cerivastatin [hsdb]
cerivastatin [who-dd]
SCHEMBL16346
SCHEMBL16347
SEERZIQQUAZTOL-ANMDKAQQSA-N
DTXSID9022786
sr-01000763520
SR-01000763520-3
CHEBI:94755
AKOS030558488
Q423439
BRD-K81169441-236-04-1
rel-(3r,5s,e)-7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoicacid
CS-0105635
HY-129458
6-heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3r,5s,6e)-
rel-(3r,5s,e)-7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl)-3,5-dihydroxyhept-6-enoic acid
6-heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1- methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3r,5s,6e)-

Research Excerpts

Overview

Cerivastatin (Baycol) is a third generation statin, which has been implicated in cases of fatal rhabdomyolysis. It is administered to hypercholesterolemic patients at doses equivalent to 1-3% of the doses of other statins.

ExcerptReferenceRelevance
"Cerivastatin (Baycol) is a third generation statin, which has been implicated in cases of fatal rhabdomyolysis."( Severe obstructive sleep apnea after cerivastatin therapy: a case report.
Ebben, MR; Sethi, NK; Spielman, AJ, 2008
)
1.34
"Cerivastatin is a novel, synthetic and the most pharmacologically potent inhibitor of HMG-CoA reductase."( Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Golab, J; Jakóbisiak, M; Kaminski, R; Kopec, M; Koronkiewicz, M; Kozar, K; Legat, M; Nowis, D; Skierski, JS, 2004
)
2.49
"Cerivastatin is a synthetic HMG-CoA reductase inhibitor with high liver selectivity, which lowers plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. "( Cerivastatin.
McClellan, KJ; McTavish, D; Wiseman, LR, 1998
)
3.19
"Cerivastatin is a novel, synthetic, highly potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that effectively reduces serum cholesterol levels at very low doses. "( Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Unger, S, 1998
)
1.95
"Cerivastatin is a novel, potent HMG-CoA reductase inhibitor. "( Lack of drug-drug interaction between cerivastatin and nifedipine.
Brendel, E; Horstmann, R; Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Sachse, R, 1998
)
2.01
"Cerivastatin is a new but structurally distinct 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin"). "( Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
Schlüter, G; von Keutz, E, 1998
)
2.02
"Cerivastatin is a new, third-generation 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin"), which is administered to hypercholesterolemic patients at doses equivalent to 1-3% of the doses of other statins. "( Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L, 1998
)
2.03
"Cerivastatin is a novel, potent HMG-CoA reductase inhibitor that effectively reduces serum cholesterol levels at low daily doses."( Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.
Mück, W, 1998
)
1.27
"Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. "( Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein, EA, 1998
)
1.97
"Cerivastatin is a third generation hydroxy-methyl-glutaryl-Co-enzyme A (HMG-CoA) reductase inhibitor proven to lower low-density lipoprotein (LDL) cholesterol 28% to 31% in patients with primary hypercholesterolemia when given at 0.3 mg/day. "( Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Heller, AH; Isaacsohn, J; Lane, C; Liu, MC; Mazzu, A; Stein, E; Stoltz, R, 1999
)
1.97
"Cerivastatin is a noncomplicated drug with respect to its biopharmaceutical profile and bioavailability."( Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
Lettieri, J; Mazzu, A; Mück, W; Ochmann, K,
)
1.14
"Cerivastatin is a highly effective lipid-lowering agent currently licensed at doses of 0.1, 0.2, 0.3 and 0.4 mg."( Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group.
Eriksson, J; Lithell, H; Luurila, O; Olsson, A; Ose, L; Widgren, B, 1999
)
1.34
"Cerivastatin 0.8 mg is an effective and safe treatment for patients with primary hypercholesterolaemia who need aggressive LDL-C lowering in order to achieve NCEP-recommended levels."( Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Brazg, R; Dujovne, C; Insull, W; Isaacsohn, J; Kwiterovich, P; Ra, P; Ripa, S; Shan, M; Shugrue-Crowley, E; Tota, R,
)
1.16
"Cerivastatin is a currently available statin with dual elimination; it is therefore expected to cause less drug-drug interaction."( A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Boran, M; Gökçe, V; Koçak, B; Korkmaz, S; Ozdemir, O; Uzun, Y, 2000
)
1.26
"Cerivastatin is an HMG-CoA reductase inhibitor used for the treatment of patients with hypercholesterolaemia. "( Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Dunn, CI; Figgitt, DP; Plosker, GL, 2000
)
3.19
"Cerivastatin is a well tolerated and effective lipid-lowering agent for patients with hypercholesterolaemia. "( Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Dunn, CI; Figgitt, DP; Plosker, GL, 2000
)
3.19
"Cerivastatin is a third generation, synthetic statin, characterized by the highest pharmacological and therapeutic potency among currently marketed statins, and whose lipid-lowering efficacy has been demonstrated in a number of large, multicenter trials."( [Characteristics of a statine of the most recent generation].
Barbagallo, CM; Notarbartolo, A, 2001
)
1.03
"Cerivastatin is a synthetic and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. "( Cerivastatin.
Cheng-Lai, A,
)
3.02
"Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. "( Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.
Hong, L; Mirshahi, F; Mishal, Z; Opolon, P; Soria, C; Soria, J; Vannier, JP; Vincent, L, 2002
)
3.2

Effects

Cerivastatin (C) has a strong anti-proliferative effect (APE) on smooth muscle cells. It can be administered to both young and elderly patients. No potentially significant drug interactions with other CYP3A4 inhibitors have been reported.

Cerivastatin (C) has a strong anti-proliferative effect (APE) on smooth muscle cells. It can be administered to both young and elderly patients, male and female. No potentially significant drug interactions with other CYP3A4 inhibitors have been reported.

ExcerptReferenceRelevance
"Cerivastatin has a pharmacokinetic profile (high potency, bioavailability, lipophilicity and renal excretion) that is different from other statins, which may explain the high myotoxicity rate."( Controversy surrounding the safety of cerivastatin.
Davidson, MH, 2002
)
1.31
"Cerivastatin (C) has a strong anti-proliferative effect (APE) on smooth muscle cells (SMCs), whereas pravastatin (P) has a weak effect."( Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.
Arai, M; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Okubo, M; Sano, K; Takemura, G; Uno, Y; Yokoyama, H, 2004
)
1.32
"Cerivastatin has an uncomplicated pharmacokinetic profile; it can be administered to both young and elderly patients, male and female, without the need for dosage adjustments."( Preclinical and clinical pharmacology of cerivastatin.
Bischoff, H; Heller, AH, 1998
)
1.29
"Cerivastatin has a dual hepatic metabolism pathway, via the CYP3A4 and CYP2C8 isoenzymes of cytochrome P450; therefore no potentially significant drug interactions with other CYP3A4 inhibitors, for instance erythromycin and itraconazole, have been reported."( [Characteristics of a statine of the most recent generation].
Barbagallo, CM; Notarbartolo, A, 2001
)
1.03
"Cerivastatin has a pharmacokinetic profile (high potency, bioavailability, lipophilicity and renal excretion) that is different from other statins, which may explain the high myotoxicity rate."( Controversy surrounding the safety of cerivastatin.
Davidson, MH, 2002
)
1.31
"Cerivastatin (C) has a strong anti-proliferative effect (APE) on smooth muscle cells (SMCs), whereas pravastatin (P) has a weak effect."( Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.
Arai, M; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Okubo, M; Sano, K; Takemura, G; Uno, Y; Yokoyama, H, 2004
)
1.32
"Cerivastatin has an uncomplicated pharmacokinetic profile; it can be administered to both young and elderly patients, male and female, without the need for dosage adjustments."( Preclinical and clinical pharmacology of cerivastatin.
Bischoff, H; Heller, AH, 1998
)
1.29
"Cerivastatin has been tested in more than 4000 patients during extensive phase II and III studies."( Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein, EA, 1998
)
1.25
"Cerivastatin has a dual hepatic metabolism pathway, via the CYP3A4 and CYP2C8 isoenzymes of cytochrome P450; therefore no potentially significant drug interactions with other CYP3A4 inhibitors, for instance erythromycin and itraconazole, have been reported."( [Characteristics of a statine of the most recent generation].
Barbagallo, CM; Notarbartolo, A, 2001
)
1.03
"Cerivastatin 0.8 mg has greater long-term efficacy in reducing LDL-C than pravastatin 40 mg in primary hypercholesterolemia."( Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
Brazg, R; Dujovne, CA; Insull, W; Isaacsohn, J; Kwiterovich, P; Patrick, MA; Ripa, S; Shan, M; Shugrue-Crowley, E; Stein, E; Tota, R, 2001
)
2.03

Actions

Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after approximately 4 h of exposure reaching the maximum after approximately 10 h.

ExcerptReferenceRelevance
"Cerivastatin may allow successful 5FU therapy in chemoresistant patients."( Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.
Cassidy, J; Collie-Duguid, E; Wang, W, 2002
)
2.48
"Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after approximately 4 h of exposure reaching the maximum after approximately 10 h."( Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.
Dobrucki, IT; Kalinowski, L; Malinski, T, 2002
)
2.48

Treatment

Cerivastatin treatment also reduced growth, proteolytic activity due to MMP-9, and TF expression in cultured human monocyte/macrophages. Treatment with cervastatin did not affect the response to Ang II compared with bas.

ExcerptReferenceRelevance
"Cerivastatin treatment (1.0 mg/kg) inhibited the up-regulated expression of MCP-1 and TGF-beta mRNA (decreased to 48% and 34%, respectively) in diabetic SHR."( Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model.
Ando, H; Kobayashi, K; Nohara, E; Ota, T; Takamura, T; Yamashita, H, 2003
)
1.36
"Cerivastatin-treated mice showed insignificant reductions in serum TNF-alpha and IL-6 concentrations after bacterial challenge."( Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance.
Blankson, S; Chaudhry, MZ; Redmond, HP; Wang, JH, 2008
)
1.5
"One cerivastatin-treated patient experienced asymptomatic creatinine kinase, 8x the upper limit of normal (ULN) elevation on the last day of the study, which resolved 6 days after the completion of the study."( Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Heller, AH; Isaacsohn, J; Lane, C; Liu, MC; Mazzu, A; Stein, E; Stoltz, R, 1999
)
1.01
"Cerivastatin treatment lasted 8 weeks and produced significant reductions in low density lipoprotein-cholesterol (LDL-C) levels from baseline compared with placebo."( Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
Deslypere, JP; Durrington, PN; Farnier, M; Hanefeld, M; Ose, L; Schmage, N,
)
1.1
"Cerivastatin treatment (>or=0.01 micromol/L) also reduced growth, proteolytic activity due to MMP-9, and TF expression in cultured human monocyte/macrophages."( An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
Aikawa, M; Fukumoto, Y; Furukawa, Y; Libby, P; Rabkin, E; Schoen, FJ; Shiomi, M; Sugiyama, S; Voglic, SJ, 2001
)
1.32
"Cerivastatin treatment upregulated eNOS expression and reduced the interaction of the cytosolic protein with the 3'-untranslated region of eNOS mRNA."( Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits.
Arriero, MM; Casado, S; Farré, J; Fortes, J; García, R; González-Fernandez, F; Jiménez, A; López-Blaya, A; López-Farré, A; Millás, I; Rico, L; Sánchez De Miguel, L; Velasco, S, 2001
)
1.03
"Pretreatment of cerivastatin suppressed the adriamycin-induced apoptosis of cultured cardiomyocytes of neonatal rats."( 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Asakawa, M; Hasegawa, H; Komuro, I; Mizukami, M; Nagai, T; Takano, H; Yamamoto, R, 2003
)
0.65
"Treatment with cerivastatin did not affect the response to Ang II compared with baseline."( The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.
Delles, C; Fleischmann, EH; John, S; Schmidt, BM; Schmieder, RE; Schneider, MP, 2004
)
0.66
"Treatment with cerivastatin but not pitavastatin, pravastatin, or atorvastatin decreased basal and TNF-alpha-stimulated ET-1 release from PAECs in a dose-dependent manner (1-10 microM)."( Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M, 2006
)
0.67
"Treatment with cerivastatin alone decreased plasma cholesterol levels by 45% and increased creatine kinase (CK) levels by more than 10-fold (a marker of myotoxicity)."( Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Anayama, H; Hamajyo, H; Hirakata, M; Ishikawa, E; Nagai, H; Nishimoto, T; Tozawa, R, 2007
)
0.68
"Treatment with cerivastatin for 24 hours reduced the calcium response of VSMCs to Ang II."( Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.
Egashira, K; Hirano, K; Ichiki, T; Iino, N; Kanaide, H; Shimokawa, H; Takeda, K; Takeshita, A; Tokunou, T, 2001
)
0.65

Toxicity

Cerivastatin is safe and effective for patients with hypercholesterolemia who require aggressive LDL cholesterol lowering to achieve NCEP-recommended targets. Total cholesterol, LDL-cholesterol and triglyceride concentrations were significantly lowered by cervastatin. No significant effect of cerivstatin on serum creatininkinase concentrations was observed.

ExcerptReferenceRelevance
" Adverse events were mild and occurred less frequently in the participants receiving cerivastatin than in those receiving placebo."( Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
Heller, AH; Kaiser, L; Lettieri, J; Mazzu, A; Mullican, W, 1998
)
0.74
" Adverse effects were similar to those observed with other statins and primarily involved the liver and muscle tissue."( Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
Schlüter, G; von Keutz, E, 1998
)
0.58
" There was no significant difference between the incidence of adverse effects with cerivastatin and comparator statins or between cerivastatin and other statins with respect to clinically significant increases in either hepatic enzymes or creatine phosphokinase."( Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L, 1998
)
0.81
" Cerivastatin was well tolerated, with the type and incidence of clinical adverse effects comparable to that of placebo and comparator drugs."( Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein, E, 1998
)
2.65
" This study has shown that cerivastatin can be safely combined with either cholesytramine or probucol to provide a safe and highly effective hypolipidemic treatment regimen for patients with heterozygous familial hypercholesterolemia."( Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
Kajinami, K; Koizumi, J; Mabuchi, H, 1998
)
0.88
" Cerivastatin was well tolerated, with the type and incidence of clinical adverse effects comparable to that of placebo and comparator drugs."( Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein, E, 1998
)
2.65
" Adverse events were mild and transient."( Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Heller, AH; Isaacsohn, J; Lane, C; Liu, MC; Mazzu, A; Stein, E; Stoltz, R, 1999
)
0.53
" Treatments were well tolerated, and the incidence of adverse effects was similar in both groups."( Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin.
Hanna, K; Leiter, LA, 1999
)
0.61
" Only two withdrawals due to adverse events during active treatment occurred, neither of which was considered to be due to the study medication."( Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
Deslypere, JP; Durrington, PN; Farnier, M; Hanefeld, M; Ose, L; Schmage, N,
)
0.38
"2 mg group withdrew owing to adverse events."( Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group.
Eriksson, J; Lithell, H; Luurila, O; Olsson, A; Ose, L; Widgren, B, 1999
)
0.61
" There was no significant difference between the groups in haemoglobin A1c, adverse events or increases in liver and muscle enzymes during the study period."( Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators.
Chajek-Shaul, T; Maislos, M; Maritz, FJ; Markel, A; Rubinstein, A; Soule, SG; Stolero, D; Tal, S, 1999
)
0.61
" The most commonly reported adverse events included headache, pharyngitis and rhinitis (4 - 6%)."( Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Brazg, R; Dujovne, C; Insull, W; Isaacsohn, J; Kwiterovich, P; Ra, P; Ripa, S; Shan, M; Shugrue-Crowley, E; Tota, R,
)
0.44
" Both drugs were well tolerated, with most adverse events being mild."( Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
Ferdinand, K; Krug-Gourley, S; Poland, M; Saunders, E; Tonkon, MJ; Yellen, LG, 2000
)
0.62
" Cerivastatin is safe and effective for patients with hypercholesterolemia who require aggressive LDL cholesterol lowering to achieve NCEP-recommended targets."( Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
Dujovne, CA; Hunninghake, D; Knopp, R; Kwiterovich, P; McBride, TA; Poland, M, 2000
)
1.47
" The most common adverse events, including headache (4), dyspepsia (4), and rash (4), were equally distributed between groups."( Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.
Heller, AH; Isaacsohn, J; Lettieri, J; Mazzu, A; Zinny, M, 2001
)
0.54
" Adverse events occurred in 3% of patients, and included myositis (0."( Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program.
Gibbs, H; Grace, K; Hyatt, R; Jones, DL; Lowenthal, SP; Maneval, K; O'Malley, PG; Sheikh, M; Spain, J; Swiecki, J; Taylor, AJ; West, M, 2001
)
0.31
" The possibility of uncommon but potentially serious adverse effects suggests that these programs require appropriate monitoring."( Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program.
Gibbs, H; Grace, K; Hyatt, R; Jones, DL; Lowenthal, SP; Maneval, K; O'Malley, PG; Sheikh, M; Spain, J; Swiecki, J; Taylor, AJ; West, M, 2001
)
0.31
"Potential cost differences between statins are driven primarily by drug costs, differential lowering effects on low-density lipoprotein cholesterol (LDL-C) levels, and adverse drug interactions and reactions."( Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
Agro, A; Braeken, A; Hanna, K; McPherson, R, 2001
)
1.75
"6%) because of an adverse event."( Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
Agro, A; Braeken, A; Hanna, K; McPherson, R, 2001
)
1.75
" Cerivastatin was well tolerated; the most commonly reported adverse events were arthralgia, headache, pharyngitis, and rhinitis."( Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
Brazg, R; Dujovne, CA; Insull, W; Isaacsohn, J; Kwiterovich, P; Patrick, MA; Ripa, S; Shan, M; Shugrue-Crowley, E; Stein, E; Tota, R, 2001
)
1.5
" This may result in the plasma and tissue concentrations of statins, and their active metabolites, increasing to levels that are toxic for striated muscle."( [Myotoxicity and rhabdomyolisis due to statins].
Banga, JD, 2001
)
0.31
" Patients with concurrent prescriptions were surveyed for current use, awareness of withdrawal/warnings, adverse effects and creatine phosphokinase (CK) results."( High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.
Bult, J; Keehr, LM; Sai, TT; Schiff, GD, 2002
)
0.31
" The most important and clinically relevant adverse effect reported with statins is myopathy."( [Adverse effects of statins].
Andréjak, M; Caron, J; Gras, V; Massy, ZA,
)
0.13
" The aim of this study was to investigate the pharmacokinetics, and adverse effects of cerivastatin combined with tacrolimus in renal transplant patients."( Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
Haas, CS; Kunzendorf, U; Liebelt, J; Oberbarnscheidt, M; Renders, L; Schöcklmann, HO, 2003
)
0.89
" Lipid concentrations, routine laboratory parameters and adverse events were obtained and analysed throughout the study period of 6 months."( Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
Haas, CS; Kunzendorf, U; Liebelt, J; Oberbarnscheidt, M; Renders, L; Schöcklmann, HO, 2003
)
0.67
" Total cholesterol, LDL-cholesterol and triglyceride concentrations were significantly lowered by cerivastatin whereas no significant effect of cerivastatin on serum creatininkinase concentrations was observed and no adverse effects were documented."( Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
Haas, CS; Kunzendorf, U; Liebelt, J; Oberbarnscheidt, M; Renders, L; Schöcklmann, HO, 2003
)
0.89
" As with all statins, there is a marked increase in adverse effects when the dose is titrated from 40 to 80 mg, and rosuvastatin demonstrates a similar dose/toxicity relationship."( Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
Davidson, MH, 2004
)
0.32
"We reviewed rosuvastatin-associated adverse events reported to the US Food and Drug Administration over its first year of marketing."( The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
Alsheikh-Ali, AA; Ambrose, MS; Karas, RH; Kuvin, JT, 2005
)
0.33
"Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are associated with adverse skeletal muscle effects, but the underlying mechanisms remain unclear."( Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.
Criswell, KA; Evans, MG; Loi, CM; Rothwell, CE; Seachrist, JL, 2005
)
0.59
" Pravastatin was not toxic up to 1 mmol/l."( Toxicity of statins on rat skeletal muscle mitochondria.
Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A, 2006
)
0.33
" The risk of adverse effects is increased with their concomitant use."( [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Anić, B; Bosnić, D; Cikes, N; Huić, M; Markeljević, J; Mayer, M; Pazanin, L; Sentić, M,
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are associated with adverse skeletal muscle toxicity, but the underlying mechanism remains unclear."( Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats.
Kiyosawa, N; Maeda, N; Manabe, S; Mori, K; Nezu, Y; Obayashi, H; Sanbuissho, A; Tani, Y; Yokota, H, 2011
)
1.81
" These results indicate that muscle cells may be particularly susceptible to a statin-induced suppression of essential antioxidant selenoproteins, which provides an explanation for the disposition of these drugs to evoke adverse muscular side-effects."( Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells.
Fuhrmeister, J; Kromer, A; Moosmann, B; Tews, M, 2012
)
0.63
"Skeletal muscle toxicity including rhabdomyolysis in severe case is a major side effect of low-density lipoprotein cholesterol-lowering statin drugs."( Association of miR-145 With Statin-Induced Skeletal Muscle Toxicity in Human Rhabdomyosarcoma RD Cells.
Nakajima, M; Nakanishi, T; Saito, S; Shirasaki, Y; Tamai, I, 2017
)
0.46

Pharmacokinetics

Cerivastatin is readily and completely absorbed from the gastrointestinal tract. Plasma concentrations reach a peak 2 to 3 hours postadministration followed by a monoexponential decay with an elimination half-life (t1/2beta) of 2 to3 hours.

ExcerptReferenceRelevance
"Twenty-one healthy, male volunteers completed this double-blind, randomized, two-period, crossover study to determine the possible pharmacodynamic and pharmacokinetic interaction of the concomitant administration of rivastatin and warfarin sodium in healthy volunteers."( No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin.
Duursema, L; Groenewoud, G; Hundt, HK; Middle, MV; Müller, FO; Ritter, W; Schall, R, 1995
)
0.29
" The decrease in mean AUC was now approximately 8-16% depending on the time of pretreatment (1-hour-interval: 16%, 5-hour-interval: 8%), and Cmax decreased by approximately 32%, irrespective of the time of pretreatment."( Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Frey, R; Kuhlmann, J; Lücker, PW; Mück, W; Ritter, W; Wetzelsberger, N, 1997
)
0.54
" had a modest influence on cerivastatin clearance, leading to a mean increase in the maximum plasma concentration (Cmax) of 13% and a slightly increased terminal half-life (approximately 10%), resulting in a mean elevation of the area under the curve (AUC) of 21%; time to peak (tmax) remained unchanged."( Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Unger, S, 1998
)
0.81
" In addition, the small increase in cerivastatin half-life does not predict an accumulation beyond steady state."( Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Unger, S, 1998
)
0.78
"During the world-wide clinical development of the HMG-CoA reductase inhibitor cerivastatin, pharmacokinetic data have been collected from studies performed in Europe, North America and Japan, covering different ethnic groups, mainly Caucasians and Japanese subjects, but also Black and Hispanics."( Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Ahr, G; Kawano, K; Mück, W; Unger, S, 1998
)
0.75
" The inter-ethnic comparison was based on retrospective analysis of the overall pharmacokinetic data pool (n = 340 complete profiles) in the key parameters AUC, Cmax, tmax and t1/2, assessed via non-compartmental methods."( Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Ahr, G; Kawano, K; Mück, W; Unger, S, 1998
)
0.52
" Retrospective analysis of the complete pharmacokinetic data pool revealed that there are no statistically significant differences in dose-normalized AUC- and Cmax-values."( Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Ahr, G; Kawano, K; Mück, W; Unger, S, 1998
)
0.52
" Pharmacokinetic parameters, including area under the concentration curve (AUC), peak plasma concentration (Cmax), time to Cmax (tmax), and elimination half-life (t1/2), were similar between the two age groups."( Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
Heller, AH; Kaiser, L; Lettieri, J; Mazzu, A; Mullican, W, 1998
)
0.51
"4-mg doses with no change in time to maximum concentration or the elimination half-life in plasma."( Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Heller, AH; Isaacsohn, J; Lane, C; Liu, MC; Mazzu, A; Stein, E; Stoltz, R, 1999
)
0.53
" In addition, single-dose pharmacokinetic variables for cerivastatin, including area under the curve (AUC(0-24)), peak concentration (C(max)), time to peak concentration (T(max)), and elimination half-life (t1/2), were examined with and without concurrent digoxin dosing."( Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Kaiser, L; Lettieri, JT; Mazzu, AL; Weber, P, 1999
)
0.8
" Indeed, pharmacokinetic interactions (e."( New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Baetta, R; Bellosta, S; Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R, 1999
)
0.3
" Cerivastatin is readily and completely absorbed from the gastrointestinal tract, with plasma concentrations reaching a peak 2 to 3 hours postadministration followed by a monoexponential decay with an elimination half-life (t1/2beta) of 2 to 3 hours."( Clinical pharmacokinetics of cerivastatin.
Mück, W, 2000
)
1.51
" Pharmacokinetic parameters [AUC(0-infinity), AUC(0-tn), peak concentration (Cmax), time to reach Cmax (tmax), and half-life (t1/2)] were determined for parent statins and major metabolites."( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000
)
0.53
" However, itraconazole dramatically increased atorvastatin AUC (150%), Cmax (38%), and t1/2 (30%) (P < ."( Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P, 2000
)
0.53
" The Cmax in older females was 30% higher than in age-matched males or younger males and females."( Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.
Heller, AH; Isaacsohn, J; Lettieri, J; Mazzu, A; Zinny, M, 2001
)
0.54
"2 mg cerivastatin sodium followed by a 4-hour dialysis session for pharmacokinetic profiling."( The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
Galle, PR; Jäger, W; Mück, W; Park, S; Schwarting, A; Voith, B; Wandel, E, 2001
)
1.13
" The best correlation to the AUC and Cmax of unbound cerivastatin was found with serum albumin concentration."( Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance.
Freudenthaler, SM; Gleiter, CH; Gundert-Remy, UM; Heyen, P; Kuhlmann, J; Mück, W; Müller, GA; Schmage, N; Vormfelde, SV, 1999
)
0.88
" Pharmacokinetic parameters were calculated on Day 1 and 3 months after initiation of cerivastatin therapy."( Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.
Czock, D; Kunzendorf, U; Renders, L; Schöcklmann, H, 2003
)
0.81
" The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22."( Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
Ishii, T; Ishikawa, CT; Miyashita, Y; Murano, T; Ozaki, H; Shirai, K; Toyoda, A, 2005
)
0.95
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Furthermore, the terminal half-life predictions for all three compounds were within 2-fold of the observed values."( Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes.
Gardiner, P; Paine, SW; Parker, AJ; Riley, RJ; Webborn, PJ, 2008
)
0.6
" The purpose of this study was to describe the transporter-/enzyme-mediated drug-drug interactions (DDIs) of CER with CsA or GEM based on unified physiologically based pharmacokinetic (PBPK) models and to investigate whether the DDIs can be quantitatively analyzed by a bottom-up approach."( Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T, 2018
)
0.72

Compound-Compound Interactions

The mechanism involved in the clinically relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA) has not yet been clarified. Cytostatic/cytotoxic effects of cervastatin used alone or in the combination with chemotherapeutics were measured with MTT assay. Reduced function of OATP1B1 related to genetic variation and drug-Drug interactions likely contributed to cerivastsatin-induced rhabdomyolysis.

ExcerptReferenceRelevance
" To study the drug-drug interaction potential, the mutual effects of cerivastatin and nifedipine were investigated in a controlled, randomized, non-blind 3-way crossover study in healthy male subjects."( Lack of drug-drug interaction between cerivastatin and nifedipine.
Brendel, E; Horstmann, R; Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Sachse, R, 1998
)
0.81
"Pharmacokinetic drug-drug interactions influence drug efficacy, tolerability, and compliance."( Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.
Mück, W, 1998
)
0.55
" The aim of this study was to test the efficacy and possible drug-drug interactions of the new HMG-CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)-treated renal transplant patients."( Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R, 2001
)
0.74
" Based on knowledge of pharmacokinetic and biopharmaceutical properties, a well balanced link between in vitro investigations and carefully selected in vivo interaction studies allows full assessment of the potential of a new drug to cause clinically relevant pharmacokinetic drug-drug interactions, prediction of a lack of interactions and derivation of the proper dose recommendations."( Clinical-pharmacological strategies to assess drug interaction potential during drug development.
Kuhlmann, J; Mück, W, 2001
)
0.31
"The mechanism involved in the clinically relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA) has not yet been clarified."( Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.
Itoh, T; Li, AP; Sato, H; Shitara, Y; Sugiyama, Y, 2003
)
0.76
" However, the pharmacokinetics of HMG-CoA reductase inhibitors when administered in combination with sirolimus and cyclosporin A (CsA) have not been determined."( Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.
Czock, D; Kunzendorf, U; Renders, L; Schöcklmann, H, 2003
)
0.58
" Cytostatic/cytotoxic effects of cerivastatin used alone or in the combination with chemotherapeutics were measured with MTT assay."( Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Golab, J; Jakóbisiak, M; Kaminski, R; Kopec, M; Koronkiewicz, M; Kozar, K; Legat, M; Nowis, D; Skierski, JS, 2004
)
2.05
" However, considering the possibly concentrated high unbound concentrations of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metabolism of CER appears to be the main mechanism for the clinically relevant drug-drug interaction."( Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction
Hirano, M; Sato, H; Shitara, Y; Sugiyama, Y, 2004
)
0.52
"An analysis of a case-control study of rhabdomyolysis was conducted to screen for previously unrecognized cytochrome P450 enzyme (CYP) 2C8 inhibitors that may cause other clinically important drug-drug interactions."( A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.
Floyd, JS; Heckbert, SR; Kaspera, R; Kwok, PY; Lumley, T; Marciante, KD; Psaty, BM; Tamraz, B; Totah, RA; Weiss, NS; Wiggins, KL, 2012
)
0.64
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"Reduced function of OATP1B1 related to genetic variation and drug-drug interactions likely contributed to cerivastatin-induced rhabdomyolysis."( OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
Chu, C; Floyd, JS; Fukushima, H; Heckbert, SR; Kaspera, R; Kroetz, DL; Kwok, PY; Ma, B; Marciante, KD; Psaty, BM; Tamraz, B; Totah, RA; Wolfe, AR, 2013
)
0.83
" The purpose of this study was to describe the transporter-/enzyme-mediated drug-drug interactions (DDIs) of CER with CsA or GEM based on unified physiologically based pharmacokinetic (PBPK) models and to investigate whether the DDIs can be quantitatively analyzed by a bottom-up approach."( Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.
Kim, SJ; Sugiyama, Y; Toshimoto, K; Yao, Y; Yoshikado, T, 2018
)
0.72

Bioavailability

The mean absolute oral bioavailability of cerivastatin is 60% because of presystemic first-pass effects. The influence of concomitant administration of erythromycin, a potent CYP3A4 inhibitor, on cervastatin bioavailability and pharmacokinetics was investigated.

ExcerptReferenceRelevance
" When both drugs were administered concomitantly in the morning under fasting conditions, a decrease in relative bioavailability by 21% could be observed, possibly due to irreversible adsorption of the statin to the resin."( Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Frey, R; Kuhlmann, J; Lücker, PW; Mück, W; Ritter, W; Wetzelsberger, N, 1997
)
0.54
"To determine the absolute bioavailability of the HMG-CoA reductase inhibitor cerivastatin, 12 healthy young male volunteers received single doses of either 100 micrograms as a 1-minute bolus infusion or 200 micrograms orally as tablets in a controlled, randomized crossover study."( Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
Ahr, G; Kuhlmann, J; Mück, W; Ochmann, K; Ritter, W; Unger, S; Wingender, W, 1997
)
0.76
" The influence of concomitant administration of erythromycin, a potent CYP3A4 inhibitor, on cerivastatin bioavailability and pharmacokinetics was investigated."( Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Unger, S, 1998
)
0.73
" The presented study was performed to determine the influence of the gastric acid secretion inhibitor omeprazole on bioavailability and pharmacokinetics of cerivastatin."( The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.
Mück, W; Ochmann, K; Rohde, G; Sachse, R, 1998
)
0.75
" The plasma concentration/time profile of the tablet is similar to an aqueous oral solution (relative bioavailability is 100%)."( Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
Lettieri, J; Mazzu, A; Mück, W; Ochmann, K,
)
0.42
" The mean absolute oral bioavailability of cerivastatin is 60% because of presystemic first-pass effects."( Clinical pharmacokinetics of cerivastatin.
Mück, W, 2000
)
0.86
"Short-term lipid-lowering therapy with cerivastatin can improve endothelial function and NO bioavailability after two weeks in patients with hypercholesterolemia."( Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.
Delles, C; Jacobi, J; John, S; Schlaich, MP; Schmieder, RE; Schmitz, G; Schneider, M, 2001
)
0.8
" Although improvement in NO bioavailability has been attributed to the lowering of serum cholesterol levels, recent studies suggest that HMG-CoA reductase inhibitors, statins, may have direct effects on NO bioavailability by little known mechanisms that are independent of serum cholesterol levels."( Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.
Dobrucki, IT; Kalinowski, L; Malinski, T, 2002
)
1.76
" The greatest advantages, of cerivastatin, however, are its lipophilicity, its high bioavailability of about 60% after oral application and its potency at 100-fold lower doses compared to other lipophilic statins."( Cerivastatin: a cellular and molecular drug for the future?
Siegel-Axel, DI, 2003
)
2.05
" Cerivastatin shows the highest oral bioavailability within its class."( [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
Müller, M; Zeitlinger, M, 2003
)
1.49
"The aim of this study was to investigate whether the HMG-CoA reductase inhibitor cerivastatin alters the nitric oxide (NO) bioavailability of porcine aortic endothelial cell cultures and of native porcine coronary endothelium, after short-term (minutes) and long-term (24-hour) treatment with cerivastatin (electrochemical NO sensor)."( The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.
Bartels, H; Berkels, R; Klaus, W; Nouri, SK; Roesen, P; Roesen, R; Taubert, D, 2003
)
0.83
" Despite a significant improvement in lipid profile under statin therapy, no improvement of endothelial dysfunction in terms of nitric oxide bioavailability could be detected."( Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
Balletshofer, BM; Enderle, M; Ferenc Pap, A; Goebbel, S; Häring, HU; Matthaei, S; Petzinna, D; Rittig, K; Schmölzer, I; Wascher, TC; Westermeier, T, 2005
)
0.33
" Dose optimization and use of novel controlled drug delivery systems may help in increasing the bioavailability and distribution of statins to the bone microenvironment."( Statins and osteoporosis: new role for old drugs.
Jadhav, SB; Jain, GK, 2006
)
0.33
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

The influence of food and time of drug dosing on the pharmacokinetics of cerivastatin, a potent HMG-CoA reductase inhibitor, was evaluated in 24 healthy male subjects.

ExcerptRelevanceReference
" While the mean AUC of the metabolite M1 following the combined dosing was decreased by 60% compared with mono-dosing, the mean AUC of M23 exhibited an increase of approximately 60%."( Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Kuhlmann, J; Mück, W; Ochmann, K; Rohde, G; Unger, S, 1998
)
0.51
" Cerivastatin has an uncomplicated pharmacokinetic profile; it can be administered to both young and elderly patients, male and female, without the need for dosage adjustments."( Preclinical and clinical pharmacology of cerivastatin.
Bischoff, H; Heller, AH, 1998
)
1.48
"Phase IIa clinical studies with cerivastatin--including 2 pilot US and European dose-ranging studies, and 1 US dose-scheduling study--were conducted to establish a dosage regimen and effective therapeutic doses of cerivastatin in the treatment of hypercholesterolemia."( Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.
Hunninghake, DB, 1998
)
0.9
"The influence of food and time of drug dosing on the pharmacokinetics of cerivastatin, a potent HMG-CoA reductase inhibitor, was evaluated in 24 healthy male subjects between 21 and 44 years of age."( Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.
Frey, R; Mück, W; Unger, S; Voith, B, 2000
)
0.86
" Cerivastatin can be administered independent of meal intake at dinner or at bedtime, the preferred time of dosing for statins because the rate of hepatic cholesterol synthesis is greatest at night."( Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.
Frey, R; Mück, W; Unger, S; Voith, B, 2000
)
1.54
" However, the generalizability, speed of onset, and dose-response characteristics of this effect are uncertain."( Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
Lowenthal, SP; Ridker, PM; Rifai, N, 2001
)
0.57
"8 mg of cerivastatin), no clear dose-response effect of cerivastatin on CRP was observed, nor was there any substantive correlation between the magnitude of change in CRP and the magnitude of change in LDL-C (r=-0."( Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
Lowenthal, SP; Ridker, PM; Rifai, N, 2001
)
1.01
" Based on the observed moderate increase in cerivastatin mean exposure, patients should be started at the lower end of the recommended dosing range and subsequent titration should be performed with caution."( The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
Galle, PR; Jäger, W; Mück, W; Park, S; Schwarting, A; Voith, B; Wandel, E, 2001
)
0.88
" Six product brands encompassing 20 dosage strengths have been available during the past two years."( Managed care trends in statin usage.
Bazalo, GR, 2001
)
0.31
" Trends in market share, mean daily dose, and dosage distribution of the six current statin brands were examined."( Managed care trends in statin usage.
Bazalo, GR, 2001
)
0.31
"Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI."( Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.
Burne-Taney, M; Daniels, F; Kasiske, B; Keane, W; O'Donnell, M; Rabb, H; Yokota, N,
)
1.57
" The four cases illustrate the importance of considering the potential for drug interactions and making appropriate dosage adjustments for renal insufficiency in patients receiving HMG CoA reductase therapy."( HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.
Bagnall, F; Choy, T; Cordato, D; Dunn, R; Hitchens, N; Huynh, T; Johnstone, K; Yang, F,
)
0.13
" A clinical pharmacist was responsible for laboratory monitoring, patient counseling, and the initiation and dosage adjustment of an appropriate 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) using a dosing algorithm and monitoring guidelines."( A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients.
Abbott, KC; McMillan, RJ; Sheikh, AM; Viola, RA; Welch, PG; Yuan, CM, 2002
)
0.31
" This was similar for both statins and was treatment-duration dependent, only occurring after 10 days had elapsed even if the dose was increased, and still occurring after this time when dosing was terminated earlier as a result of morbidity."( Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.
Bigley, A; Marsden, AM; Randall, K; Scott, RC; Westwood, FR, 2005
)
0.33
" As for other statins, only limited data was available for the relationship between the dosage and the rate of myopathy."( [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M, 2005
)
0.68
" Selectivity of these potential biomarkers was tested by dosing rats with the cardiotoxicant isoproterenol (0."( Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling.
Aranibar, N; Dai, J; Janovitz, EB; Lehman-McKeeman, L; Lowe-Krentz, L; Rathmacher, J; Reily, M; Robertson, D; Stryker, S; Vassallo, JD; Zhang, Y, 2011
)
0.37
" There were also increases in plasma 2HG in CER-treated rats on Days 8 and 11 and in TMPD-treated rats at 24 hr after dosing and increases in plasma hexanoylcarnitine in CER-treated rats on Day 11 and in TMPD-treated rats at 6 and 24 hr after dosing."( Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats.
Asai, F; Kobayashi, N; Nezu, Y; Obayashi, H; Shirai, M; Yamoto, T, 2017
)
0.46
" Cerivastatin log dose-response data were linear over the commonly prescribed dose range."( Cerivastatin for lowering lipids.
Adams, SP; Alaeiilkhchi, N; Tiellet, N; Wright, JM, 2020
)
2.91
" Log dose-response data over doses of 1 mg to 16 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol and triglycerides."( Pitavastatin for lowering lipids.
Adams, SP; Alaeiilkhchi, N; Wright, JM, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
dihydroxy monocarboxylic acidAny hydroxy monocarboxylic acid carrying at least two hydroxy groups.
statin (synthetic)A statin which does not occur naturally and which is not obtained by chemical transformation of a naturally occurring statin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Cerivastatin Action Pathway2143

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)IC50 (µMol)0.00500.00000.79498.9000AID241793; AID625271
Insulin receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.00010.00010.78463.3700AID625271
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.00010.00010.995010.0000AID625271
3-hydroxy-3-methylglutaryl-coenzyme A reductase Rattus norvegicus (Norway rat)IC50 (µMol)0.00560.00090.20949.0300AID1797730; AID1798004; AID1798163; AID300167; AID384740
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
visual learning3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A metabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein catabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein secretion3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
long-term synaptic potentiation3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
regulation of ERK1 and ERK2 cascade3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of amyloid-beta clearance3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
isoprenoid biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
sterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
hydroxymethylglutaryl-CoA reductase (NADPH) activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
protein binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
GTPase regulator activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
NADPH binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID1798004HMG-CoA Reductase Enzyme Assay and Inhibition of Cellular Cholesterol Synthesis Assay from Article 10.1021/jm070849r: \\Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-meth2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID1798163HMG-CoA Reductase Enzyme Assay and Inhibition of Cellular Cholesterol Synthesis Assay from Article 10.1021/jm800001n: \\(3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic Aci2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1797730HMG-CoA Reductase In Vitro Assay from Article 10.1016/j.bmc.2007.05.031: \\Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.\\2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID1221969Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698004Fraction unbound in cynomolgus monkey plasma
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID384745Partition coefficient, log P by octanol-water partitioning method2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1221975Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1301027Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size after 72 hrs by fluorescent image analysis2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1301018Cytotoxicity against human HepG2 cells assessed as reduction in cell number at 100 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1301019Cytotoxicity against human HepG2 cells assessed as reduction in cell number after 72 hrs by fluorescent image analysis2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID312173Inhibition of cholesterol synthesis in rat hepatocytes2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID312172Inhibition of HMG-CoA reductase in Sprague-Dawley rat liver microsomes2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1301022Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level at 100 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID384761Hepatotoxicity in guinea pig assessed as hepatocellular degeneration2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1698003Fraction unbound in rat plasma
AID678985TP_TRANSPORTER: Transepithelial Transport (basal to apical) in OATP1B1/MRP2 double transfected MDCKII cells2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multid
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID1301024Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size at 1 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID313912Inhibition of cholesterol synthesis in rat L6 myocyte2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
AID1698008Hepatic clearance in Wistar Hannover rat at 1 mg/kg, iv
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1301026Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size at 100 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID384744Partition coefficient, log P by reverse phase HPLC method2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID313913Selectivity, ratio of IC50 for rat hepatocyte to IC50 for rat L6 myocyte2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1301032Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential at 1 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID385211Myotoxicity in guinea pig assessed as drug dose causing >10 fold increase in plasma creatine kinase activity relative to control2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221976Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1301028Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability at 1 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID313916Ratio of Cmax for human to IC50 for rat L6 myocyte2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
AID384741Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID241793Inhibitory concentration against 3-hydroxy-3-methylglutaryl-CoA reductase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID300171Inhibition of cholesterol synthesis in C57/BL6 mouse at 30 mg/kg, po by MAICS assay2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID385189Myotoxicity in po dosed weanling Sprague-Dawley rat assessed as drug dose causing >2.5 fold increase in plasma creatine kinase activity relative to control2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1301035Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential after 72 hrs by fluorescent image analysis2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID384752Safety index, ratio of ED50 for reduction in plasma total cholesterol level to drug dose not causing >2.5 fold increase in plasma creatine kinase in guinea pig2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1301033Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential at 30 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID384742Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID312171Lipophilicity, log P of the compound2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1301023Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level after 72 hrs by fluorescent image analysis2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1221968Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID312174Inhibition of cholesterol synthesis in rat L6 cells2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID1698005Ratio of drug level in Wistar Hannover rat blood to plasma administered through iv dosing by LC-MS/MS analysis
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID300167Inhibition of rat microsomal HMG-CoA reductase assessed as inhibition of cholesterol synthesis after 30 mins2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384751Myotoxicity in guinea pig assessed as drug dose causing >2.5 fold increase in plasma creatine kinase activity relative to control2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1301017Cytotoxicity against human HepG2 cells assessed as reduction in cell number at 30 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384748Reduction in plasma total cholesterol level in guinea pig after 10 days2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID300168Inhibition of cholesterol synthesis in rat liver hepatocytes after 4 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1301029Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability at 30 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221977Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID384743Selectivity index, ratio of IC50 for cholesterol synthesis in rat L6 cells to IC50 for cholesterol synthesis in rat hepatocytes2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID300169Inhibition of cholesterol synthesis in rat L6 cells after 3 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID678966TP_TRANSPORTER: Transepithelial Transport (basal to apical) in OATP1B1/BCRP double transfected MDCKII cells2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multid
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1221970Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID503308Antiproliferative activity against human PC3 cells at 30 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID300170Selectivity index, ratio of IC50 for rat L6 cells to IC50 for rat hepatocytes2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1301030Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability at 100 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID312175Ratio of IC50 for cholesterol synthesis in rat myocytes to rat hepatocytes2008Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
AID1301016Cytotoxicity against human HepG2 cells assessed as reduction in cell number at 1 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID445447Clearance in human assessed as liver blood flow2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID313915Cmax in human2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1301020Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level at 1 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID384769Reduction in plasma total cholesterol level in guinea pig at 1.2 mg/kg after 10 days relative to control2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID1697999Dissociation constant, acidic pKa of compound measured up to 18 mins by capillary electrophoresis
AID679109TP_TRANSPORTER: transepithelial transport in L-MDR1 cells2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID385190Safety index, ratio of ED50 for inhibition of hepatic cholesterol synthesis in Sprague-Dawley rat to drug dose not causing >2.5 fold increase in plasma creatine kinase level in weanling Sprague-Dawley rat2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID539467Lipophilicity, log D of compound at pH 72010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID678959TP_TRANSPORTER: uptake in OATP1B1-expressing HEK293 cells2005Pharmacogenetics and genomics, Jul, Volume: 15, Issue:7
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
AID679136TP_TRANSPORTER: Transepithelial Transport (basal to apical) in OATP1B1/MDR1 double transfected MDCKII cells2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multid
AID1698016Dissociation constant, basic pKa of compound measured up to 18 mins by capillary electrophoresis
AID1301021Cytotoxicity against human HepG2 cells assessed as increase in intracellular free calcium level at 30 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1698010Hepatic clearance in human administered through iv dosing
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID384747Inhibition of hepatic cholesterol synthesis in po dosed Sprague-Dawley rat assessed as incorporation of [14C]acetate into hepatic sterols2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1698002Intrinsic clearance in cryopreserved human hepatocytes at 1 uM measured up to 120 mins by LC-MS/MS analysis
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1698011Fraction unbound in human plasma
AID384740Inhibition of HMGR in rat hepatic microsomes assessed as conversion of [14C]HMG-CoA to [14C]mevalonic acid2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID313911Inhibition of cholesterol synthesis in rat hepatocyte2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
AID1301031Cytotoxicity against human HepG2 cells assessed as increase in membrane permeability after 72 hrs by fluorescent image analysis2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1301025Cytotoxicity against human HepG2 cells assessed as reduction in nuclear size at 30 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1301034Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial membrane potential at 100 uM after 72 hrs by fluorescent image analysis relative to untreated control2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID385182Myotoxicity in guinea pig assessed as increase in plasma creatine kinase activity at 1.2 mg/kg after 10 days2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346838Rat hydroxymethylglutaryl-CoA reductase (Lanosterol biosynthesis pathway)2001The American journal of cardiology, Mar-08, Volume: 87, Issue:5A
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
AID1346822Human hydroxymethylglutaryl-CoA reductase (Lanosterol biosynthesis pathway)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
AID1346822Human hydroxymethylglutaryl-CoA reductase (Lanosterol biosynthesis pathway)2005Biochemistry, Sep-06, Volume: 44, Issue:35
Binding thermodynamics of statins to HMG-CoA reductase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (524)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.38)18.7374
1990's53 (10.11)18.2507
2000's413 (78.82)29.6817
2010's49 (9.35)24.3611
2020's7 (1.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.26 (24.57)
Research Supply Index6.47 (2.92)
Research Growth Index6.68 (4.65)
Search Engine Demand Index67.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials91 (16.37%)5.53%
Reviews61 (10.97%)6.00%
Case Studies52 (9.35%)4.05%
Observational1 (0.18%)0.25%
Other351 (63.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of the Analgesic Effect of an ACB (Adductor Canal Block) Using a New Suture-method Catheter vs a Standard Perineural Catheter vs a Single Bolus: A Randomized, Blinded, Controlled Study [NCT03142789]Phase 4153 participants (Actual)Interventional2017-05-09Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]